Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02590510

Enrollment

Registered

2015-10-29

Start date

2015-10-31

Completion date

Unknown

Last updated

2016-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningeal Carcinomatosis

Keywords

Intrathecal chemotherapy

Brief summary

The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.

Interventions

DRUGmethotrexate

The quantity of methotrexate is different in the two groups.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

14 Years to No maximum

Healthy volunteers

Inclusion criteria

* age 14 or more * a history of solid tumor * a new clinical neurological signs and symptoms * a typical CT(Computerized Tomography,CT) or MRI(Magnetic Resonance Imaging,MRI) imaging findings * tumor cells in cerebrospinal fluid

Exclusion criteria

* KPS score \<60 * the tumor patients with organ failure * bacteria, fungi or viral meningitis

Design outcomes

Primary

Measure	Time frame
overall survival	one year

Secondary

Measure	Time frame	Description
The incidence of adverse reactions	one year	In accordance with the standard of CTCAE, an assessment will be assessed every month
KPS score	one year	In accordance with the standard of KPS(Karnofsky Performance Status,KPS) score, an assessment will be assessed every month

Contacts

Primary ContactHui Bu

buhuimy1@163.com86-13831106903

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026